[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354351-105":59,"doc-detail-354351-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluating-patient-preferences-for-clinical-trial-endpoints-in-early-stage-cancer-a-discrete-choice-experiment-in-canada","Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer - A Discrete Choice Experiment in Canada","","A discrete choice experiment quantified how Canadian adults with early-stage cancers trade off benefits and risks when clinical trial endpoints beyond overall survival (OS) are considered. Participants completed ten choice sets comparing standard-of-care profiles with new-treatment attributes including five-year OS, two-year disease advancement, pathological complete response (pCR), and short- and long-term side effects. Logistic regression estimated odds ratios with 95% confidence intervals across 103 respondents. Greater OS, lower progression risk, and reduced short-term or any long-term side effects increased preference, while long-term effects and pCR were only modestly informative.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluating-patient-preferences-for-clinical-trial-endpoints-in-early-stage-cancer-a-discrete-choice-experiment-in-canada/354351/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluating-patient-preferences-for-clinical-trial-endpoints-in-early-stage-cancer-a-discrete-choice-experiment-in-canada/354351.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the survey in this study?","Question",{"text":112,"@type":113},"The study measured how Canadian adults with early-stage cancers value different clinical trial endpoints, especially those beyond overall survival, to understand patient priorities in treatment decisions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which endpoints and treatment attributes were included in the discrete choice experiment?",{"text":117,"@type":113},"Participants compared options defined by five-year OS, two-year risk of disease advancement, likelihood of pathological complete response (pCR), and short- and long-term side effects.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors most increased participants’ odds of choosing the new treatment?",{"text":121,"@type":113},"Higher five-year OS, lower disease advancement risk, and milder or no short-term side effects versus severe side effects were associated with higher selection odds.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354351,1790291178,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":138,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":139,"faqs":140,"seo_title":141,"seo_description":67,"update_tm":142,"read_time":143,"preview_page_count":19,"preview_urls":144},4398046744996,"Article  \nEvaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer: A Discrete Choice Experiment in Canada  \nAlexis T. Mickle 1, *, Frances Simbulan 2, Bianca Li 2, Kristoph Klein-Panneton 2, Conor L. Morrison 1, Sarah Walker 1, Karissa M. Johnston 1 and Stephanie Snow 3  \nReceived: 12 March 2026  \nRevised: 14 May 2026  \nAccepted: 16 May 2026  \nPublished: 26 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Broadstreet HEOR, 177 W 7th Ave, Vancouver, BC V5Y 1L8, Canada  \n2 AstraZeneca Canada Inc., 1004 Middlegate Rd, Mississauga, ON L4Y 1M4, Canada  \n3 QEII Health Sciences Centre, Dalhousie University, 1796 Summer St, Halifax, NS B3H 3A7, Canada  \n* Correspondence: [amickle@broadstreetheor.com](amickle@broadstreetheor.com)  \nSimple Summary  \nThis survey assessed preferences among Canadian adults with early-stage cancers regarding cancer treatment evaluation, including endpoints beyond overall survival (OS), to better understand patient priorities in treatment decisions. Participants reviewed two hypothetical treatments and selected their preferred option based on five-year OS, two-year risk of cancer advancement, the likelihood of the treatment eliminating detectable cancer in tissue, and short-and long-term side effects. Among 103 respondents, treatments with higher OS, lower risk of cancer progression, which can affect quality of life and future treatment options, and reduced short-term or any long-term side effects were preferred. In supplemental questions, nearly half of participants supported access to a new treatment that lowered cancer progression, even if long-term survival benefits were not yet known. These findings highlight that, while OS remains highly influential in treatment decisions, people also prioritize delaying cancer progression and minimizing side effects when considering new therapies.  \nAbstract  \nTo quantify preferences and trade-offs for non-overall survival (OS) endpoints among Canadian adults treated for early-stage cancers, participants completed ten choice sets in a discrete choice experiment. Standard-of-care (SoC) was compared to new treatment profiles defined by five attributes: five-year OS, two-year disease advancement, pathological complete response (pCR), and short-and long-term side effects. SoC attribute levels remained constant across respondents, except OS, which varied. For the new treatment, all attributes except OS (fixed as unknown) varied. Data were analyzed using logistic regression and presented as odds ratios (ORs) with 95% confidence intervals (CIs) . Among 103 adults treated for early-stage gastrointestinal (n = 40), breast (n = 32), or lung (n = 31) cancer, median age was 59 (Q1, Q3: 43, 75) years; 46.6% were female. Each 25% decrease in SoC OS was associated with higher odds of choosing the new treatment (OR 3.49; 95% CI 2.82–4.31; p \u003C 0.01) . Reductions in disease advancement (OR 1.55; 1.26–1.91; p \u003C 0.01) and mild or no short-term side effects versus severe (OR 6.67; 4.35–10.00) significantly increased selection odds; long-term side effects and pCR showed modest, non-significant influence. When OS data were available for SoC, OS strongly influenced decisions; without OS data for new treatments, participants prioritized disease control and short-term tolerability.  \nKeywords: early-stage cancer; overall survival; clinical trial endpoints; patient preference; discrete choice experiment; health care surveys; patient preference; surrogate endpoint; disease-free survival; progression-free survival  \n1. Introduction  \nCancer remains a leading cause of death in Canada and globally [1–3] . For individuals with early-stage cancers, treatment pathways are guided by clinical risk evaluation, including cancer type, tumour stage, and biomarker status. The goal is to achieve cure and prevent recu","cbCaifbjLIr9tLJi","https://ap.wps.com/l/cbCaifbjLIr9tLJi","pdf",1490616,"English","# Simple Summary\n# Abstract\n# Introduction","[{\"question\":\"What was the purpose of the survey in this study?\",\"answer\":\"The study measured how Canadian adults with early-stage cancers value different clinical trial endpoints, especially those beyond overall survival, to understand patient priorities in treatment decisions.\"},{\"question\":\"Which endpoints and treatment attributes were included in the discrete choice experiment?\",\"answer\":\"Participants compared options defined by five-year OS, two-year risk of disease advancement, likelihood of pathological complete response (pCR), and short- and long-term side effects.\"},{\"question\":\"What factors most increased participants’ odds of choosing the new treatment?\",\"answer\":\"Higher five-year OS, lower disease advancement risk, and milder or no short-term side effects versus severe side effects were associated with higher selection odds.\"}]","Evaluating Patient Preferences for Clinical Trial Endpoints in Early-Stage Cancer - A Discrete Choice Experiment in Canada | PDF",1790110236,48,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1eadc23ded21c06d56e94e9db3a9f9dc.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f47c924f3ab3db1fd5af1ae9240e9cda.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3a3c4ee9feafc8bbe8b1b71559f7710.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d03f912a3c82199c5c7d05769cdf2f34.webp",980,1385]